These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
701 related items for PubMed ID: 11934319
1. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Shields CL, Honavar SG, Shields JA, Demirci H, Meadows AT, Naduvilath TJ. Arch Ophthalmol; 2002 Apr; 120(4):460-4. PubMed ID: 11934319 [Abstract] [Full Text] [Related]
2. Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors. Shields CL, Mashayekhi A, Cater J, Shelil A, Ness S, Meadows AT, Shields JA. Arch Ophthalmol; 2005 Jun; 123(6):765-73. PubMed ID: 15955977 [Abstract] [Full Text] [Related]
3. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation. Gündüz K, Günalp I, Yalçindağ N, Unal E, Taçyildiz N, Erden E, Geyik PO. Ophthalmology; 2004 Oct; 111(10):1917-24. PubMed ID: 15465557 [Abstract] [Full Text] [Related]
4. Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients. Shields CL, Shelil A, Cater J, Meadows AT, Shields JA. Arch Ophthalmol; 2003 Nov; 121(11):1571-6. PubMed ID: 14609913 [Abstract] [Full Text] [Related]
5. Management and outcome of retinoblastoma with vitreous seeds. Manjandavida FP, Honavar SG, Reddy VA, Khanna R. Ophthalmology; 2014 Feb; 121(2):517-24. PubMed ID: 24572675 [Abstract] [Full Text] [Related]
6. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. Shields CL, Shields JA, Needle M, de Potter P, Kheterpal S, Hamada A, Meadows AT. Ophthalmology; 1997 Dec; 104(12):2101-11. PubMed ID: 9400771 [Abstract] [Full Text] [Related]
7. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Singh A, Friedman DL, Naduvilath TJ. Am J Ophthalmol; 2002 May; 133(5):657-64. PubMed ID: 11992863 [Abstract] [Full Text] [Related]
9. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction. Demirci H, Eagle RC, Shields CL, Shields JA. Arch Ophthalmol; 2003 Aug; 121(8):1125-31. PubMed ID: 12912690 [Abstract] [Full Text] [Related]
10. Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors. Shields CL, Mashayekhi A, Cater J, Shelil A, Meadows AT, Shields JA. Am J Ophthalmol; 2004 Sep; 138(3):329-37. PubMed ID: 15364213 [Abstract] [Full Text] [Related]
11. Iodine 125 plaque radiotherapy as salvage treatment for retinoblastoma recurrence after chemoreduction in 84 tumors. Shields CL, Mashayekhi A, Sun H, Uysal Y, Friere J, Komarnicky L, Shields JA. Ophthalmology; 2006 Nov; 113(11):2087-92. PubMed ID: 16949158 [Abstract] [Full Text] [Related]
12. Risk Factors for Tumor Recurrence Following Primary Intravenous Chemotherapy (Chemoreduction) for Retinoblastoma in 869 Eyes of 551 Patients. Dalvin LA, Bas Z, Tadepalli S, Rao R, Vaidya S, Pacheco R, Shields CL. J Pediatr Ophthalmol Strabismus; 2020 Jul 01; 57(4):224-234. PubMed ID: 32687206 [Abstract] [Full Text] [Related]
13. Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors. Shields CL, Mashayekhi A, Cater J, Shelil A, Meadows AT, Shields JA. Trans Am Ophthalmol Soc; 2004 Jul 01; 102():35-44; discussion 44-5. PubMed ID: 15747743 [Abstract] [Full Text] [Related]
14. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results. Shields CL, Manjandavida FP, Arepalli S, Kaliki S, Lally SE, Shields JA. JAMA Ophthalmol; 2014 Mar 01; 132(3):319-25. PubMed ID: 24407202 [Abstract] [Full Text] [Related]
15. Practical approach to management of retinoblastoma. Shields CL, Mashayekhi A, Demirci H, Meadows AT, Shields JA. Arch Ophthalmol; 2004 May 01; 122(5):729-35. PubMed ID: 15136321 [Abstract] [Full Text] [Related]
16. Not All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in Retinoblastoma. Berry JL, Bechtold M, Shah S, Zolfaghari E, Reid M, Jubran R, Kim JW. Ophthalmology; 2017 Dec 01; 124(12):1817-1825. PubMed ID: 28655537 [Abstract] [Full Text] [Related]
17. Minimal exposure (one or two cycles) of intra-arterial chemotherapy in the management of retinoblastoma. Shields CL, Kaliki S, Shah SU, Bianciotto CG, Liu D, Jabbour P, Griffin GC, Shields JA. Ophthalmology; 2012 Jan 01; 119(1):188-92. PubMed ID: 21975042 [Abstract] [Full Text] [Related]
18. Intravenous chemoreduction or intra-arterial chemotherapy for cavitary retinoblastoma: long-term results. Rojanaporn D, Kaliki S, Bianciotto CG, Iturralde JC, Say EA, Shields CL. Arch Ophthalmol; 2012 May 01; 130(5):585-90. PubMed ID: 22652844 [Abstract] [Full Text] [Related]
19. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes. Shields CL, Ramasubramanian A, Thangappan A, Hartzell K, Leahey A, Meadows AT, Shields JA. Ophthalmology; 2009 Mar 01; 116(3):544-551.e1. PubMed ID: 19157557 [Abstract] [Full Text] [Related]